Carbon monoxide reduces neuropathic pain and spinal microglial activation by inhibiting nitric oxide synthesis in mice

PLoS One. 2012;7(8):e43693. doi: 10.1371/journal.pone.0043693. Epub 2012 Aug 22.

Abstract

Background: Carbon monoxide (CO) synthesized by heme oxygenase 1 (HO-1) exerts antinociceptive effects during inflammation but its role during neuropathic pain remains unknown. Our objective is to investigate the exact contribution of CO derived from HO-1 in the modulation of neuropathic pain and the mechanisms implicated.

Methodology/principal findings: We evaluated the antiallodynic and antihyperalgesic effects of CO following sciatic nerve injury in wild type (WT) or inducible nitric oxide synthase knockout (NOS2-KO) mice using two carbon monoxide-releasing molecules (CORM-2 and CORM-3) and an HO-1 inducer (cobalt protoporphyrin IX, CoPP) daily administered from days 10 to 20 after injury. The effects of CORM-2 and CoPP on the expression of HO-1, heme oxygenase 2 (HO-2), neuronal nitric oxide synthase (NOS1) and NOS2 as well as a microglial marker (CD11b/c) were also assessed at day 20 after surgery in WT and NOS2-KO mice. In WT mice, the main neuropathic pain symptoms induced by nerve injury were significantly reduced in a time-dependent manner by treatment with CO-RMs or CoPP. Both CORM-2 and CoPP treatments increased HO-1 expression in WT mice, but only CoPP stimulated HO-1 in NOS2-KO animals. The increased expression of HO-2 induced by nerve injury in WT, but not in NOS2-KO mice, remains unaltered by CORM-2 or CoPP treatments. In contrast, the over-expression of CD11b/c, NOS1 and NOS2 induced by nerve injury in WT, but not in NOS2-KO mice, were significantly decreased by both CORM-2 and CoPP treatments. These data indicate that CO alleviates neuropathic pain through the reduction of spinal microglial activation and NOS1/NOS2 over-expression.

Conclusions/significance: This study reports that an interaction between the CO and nitric oxide (NO) systems is taking place following sciatic nerve injury and reveals that increasing the exogenous (CO-RMs) or endogenous (CoPP) production of CO may represent a novel strategy for the treatment of neuropathic pain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD11b Antigen / metabolism
  • CD11c Antigen / metabolism
  • Carbon Monoxide / metabolism*
  • Enzyme Induction / drug effects
  • Ganglia, Spinal / drug effects
  • Ganglia, Spinal / pathology
  • Gene Expression Regulation, Enzymologic / drug effects
  • Gene Knockout Techniques
  • Heme Oxygenase-1 / biosynthesis
  • Heme Oxygenase-1 / metabolism
  • Male
  • Mice
  • Microglia / drug effects
  • Microglia / pathology*
  • Neuralgia / metabolism*
  • Neuralgia / pathology*
  • Nitric Oxide / biosynthesis*
  • Nitric Oxide Synthase Type II / deficiency
  • Nitric Oxide Synthase Type II / genetics
  • Organometallic Compounds / administration & dosage
  • Organometallic Compounds / metabolism
  • Organometallic Compounds / pharmacology
  • Pyrazines / administration & dosage
  • Pyrazines / metabolism
  • Pyrazines / pharmacology
  • Pyrroles / administration & dosage
  • Pyrroles / metabolism
  • Pyrroles / pharmacology
  • Sciatic Nerve / injuries
  • Spinal Cord / drug effects
  • Spinal Cord / pathology*

Substances

  • CD11b Antigen
  • CD11c Antigen
  • Organometallic Compounds
  • Pyrazines
  • Pyrroles
  • cyclohexyl-octahydro-pyrrolo(1,2-a)pyrazine
  • tricarbonylchloro(glycinato)ruthenium(II)
  • tricarbonyldichlororuthenium (II) dimer
  • Nitric Oxide
  • Carbon Monoxide
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Heme Oxygenase-1

Grants and funding

This work was supported by the Fundació La Marató de TV3 Barcelona [Grant: 070810] and Fondo de Investigación Sanitaria, Madrid [Grant: PS0900968], Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.